{"title":"Ferroptosis in Osteoarthritis: Current Understanding.","authors":"Yikai Liu, Zian Zhang, Yuan Fang, Chang Liu, Haining Zhang","doi":"10.2147/JIR.S493001","DOIUrl":null,"url":null,"abstract":"<p><p>Osteoarthritis (OA) is a prevalent degenerative disease in elderly people that is characterized by cartilage loss and abrasion, leading to joint pain and dysfunction. The aetiology of OA is complicated and includes abnormal mechanical stress, a mild inflammatory environment, chondrocyte senescence and apoptosis, and changes in chondrocyte metabolism. Ferroptosis is a regulated cell death modality characterized by the excessive accumulation of lipid peroxidation and mitochondrial dysfunction. The role of ferroptosis in OA pathogenesis has aroused researchers' attention in the past two years, and there is mounting evidence indicating that ferroptosis is destructive. However, the impact of ferroptosis on OA and how the regulators of ferroptosis affect OA development are unclear. Here, we reviewed the current understanding of ferroptosis in OA pathogenesis and summarized several drugs and compounds targeting ferroptosis in OA treatment. The accumulation of intracellular iron, the trigger of Fenton reaction, the excessive production of ROS, the peroxidation of PUFA-PLs, and mitochondrial and membrane damage are involved in chondrocyte ferroptosis. System X<sub>c</sub> <sup>-</sup> and GPX4 are the most important regulators that control ferroptosis. Several compounds, such as DFO and Fer-1, have been proven effective in preventing ferroptosis and slowing OA progression on animal models. Collectively, targeting ferroptosis shows great potential in treating OA.</p>","PeriodicalId":16107,"journal":{"name":"Journal of Inflammation Research","volume":"17 ","pages":"8471-8486"},"PeriodicalIF":4.2000,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11552513/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Inflammation Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/JIR.S493001","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Osteoarthritis (OA) is a prevalent degenerative disease in elderly people that is characterized by cartilage loss and abrasion, leading to joint pain and dysfunction. The aetiology of OA is complicated and includes abnormal mechanical stress, a mild inflammatory environment, chondrocyte senescence and apoptosis, and changes in chondrocyte metabolism. Ferroptosis is a regulated cell death modality characterized by the excessive accumulation of lipid peroxidation and mitochondrial dysfunction. The role of ferroptosis in OA pathogenesis has aroused researchers' attention in the past two years, and there is mounting evidence indicating that ferroptosis is destructive. However, the impact of ferroptosis on OA and how the regulators of ferroptosis affect OA development are unclear. Here, we reviewed the current understanding of ferroptosis in OA pathogenesis and summarized several drugs and compounds targeting ferroptosis in OA treatment. The accumulation of intracellular iron, the trigger of Fenton reaction, the excessive production of ROS, the peroxidation of PUFA-PLs, and mitochondrial and membrane damage are involved in chondrocyte ferroptosis. System Xc- and GPX4 are the most important regulators that control ferroptosis. Several compounds, such as DFO and Fer-1, have been proven effective in preventing ferroptosis and slowing OA progression on animal models. Collectively, targeting ferroptosis shows great potential in treating OA.
骨关节炎(OA)是老年人中一种常见的退行性疾病,其特点是软骨流失和磨损,导致关节疼痛和功能障碍。OA 的病因复杂,包括异常机械应力、轻度炎症环境、软骨细胞衰老和凋亡以及软骨细胞新陈代谢的变化。铁凋亡是一种调节性细胞死亡模式,其特点是脂质过氧化物的过度积累和线粒体功能障碍。近两年来,铁蜕变在 OA 发病机制中的作用引起了研究人员的关注,越来越多的证据表明铁蜕变具有破坏性。然而,铁凋亡对 OA 的影响以及铁凋亡的调节因子如何影响 OA 的发展尚不清楚。在此,我们回顾了目前对OA发病机理中铁色素沉着的认识,并总结了几种在OA治疗中靶向铁色素沉着的药物和化合物。细胞内铁的积累、Fenton 反应的触发、ROS 的过量产生、PUFA-PLs 的过氧化、线粒体和膜的损伤参与了软骨细胞铁变态反应。Xc 系统和 GPX4 是控制铁变态反应最重要的调节因子。在动物模型上,DFO 和 Fer-1 等几种化合物已被证明能有效预防铁蛋白沉积并减缓 OA 的进展。总之,以铁蛋白沉积为靶点在治疗 OA 方面显示出巨大的潜力。
期刊介绍:
An international, peer-reviewed, open access, online journal that welcomes laboratory and clinical findings on the molecular basis, cell biology and pharmacology of inflammation.